4-(4-chloro-3-phenyl-furo[2,3-b]pyridin-2-yl)-phenol | 877058-70-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: 4-(4-chloro-3-phenyl-furo[2,3-b]pyridin-2-yl)-phenol
• 英文别名: 4-(4-chloro-3-phenylfuro[2,3-b]pyridin-2-yl)phenol
• CAS: 877058-70-3
• 化学式: C₁₉H₁₂ClNO₂
• 分子量: 321.763
• InChiKey: AAGAZGHHLUFAIS-UHFFFAOYSA-N

物化性质

• 沸点：
  458.1±45.0 °C(Predicted)
• 密度：
  1.337±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-chloro-3-phenyl-furo[2,3-b]pyridin-2-yl)-phenol 在 palladium diacetate potassium carbonate 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 34.0h， 生成 3-phenyl-2-(4-((2-(1-piperidinyl)ethyl)oxy)phenyl)-N-(2-(3-pyridinyl)ethyl)furo[2,3-b]pyridin-4-amine
  参考文献：
  名称：

  Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: Synthesis, SAR, and pharmacokinetic properties

  摘要：

  2,3-Diarylfuro[2,3-b]pyridine-4-amines are a novel class of potent and selective inhibitors of Lck. The discovery, synthesis, and structure activity relationships of this series of inhibitors are reported. The most promising compounds were also profiled to deduce their pharmacokinetic properties. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.048
• 作为产物：
  描述：

  7-benzyl-2-(4-benzyloxy-phenyl)-3-phenyl-7H-furo[2,3-b]pyridin-4-one 在 palladium on activated charcoal 草酰氯 、 氢气 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 、 氯仿 、 乙酸乙酯 为溶剂， 反应 18.0h， 生成 4-(4-chloro-3-phenyl-furo[2,3-b]pyridin-2-yl)-phenol
  参考文献：
  名称：

  Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: Synthesis, SAR, and pharmacokinetic properties

  摘要：

  2,3-Diarylfuro[2,3-b]pyridine-4-amines are a novel class of potent and selective inhibitors of Lck. The discovery, synthesis, and structure activity relationships of this series of inhibitors are reported. The most promising compounds were also profiled to deduce their pharmacokinetic properties. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.048

文献信息

• Furanopyridine derivatives and methods of use
  申请人：Nunes J. Joseph

  公开号：US20060046977A1

  公开（公告）日：2006-03-02

  The present invention relates to furanopyridine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of modulating Lck and ACK-1 enzymes and of treating various related diseases and conditions, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma, thymoma, just to name a few, in a mammal, comprising administering to the mammal a therapeutically effective amount a compound of Formula I, as described above, and methods of manufacturing medicaments comprising the compound of Formula I.

  本发明涉及具有一般式I的呋喃吡啶化合物，以及其立体异构体、互变异构体、溶剂合物、药学上可接受的盐和衍生物，以及其前药。该发明还包括包含一种式I化合物的药物组合物，调节Lck和ACK-1酶的方法，以及治疗各种相关疾病和症状的方法，包括炎症、T细胞激活抑制、增殖、关节炎、器官移植、缺血或再灌注损伤、心肌梗死、中风、多发性硬化、炎症性肠病、克罗恩病、狼疮、过敏、1型糖尿病、牛皮癣、皮炎、哈希蒙氏甲状腺炎、干燥综合征、自身免疫性甲状腺功能亢进症、艾迪生病、自身免疫性疾病、肾小球肾炎、过敏性疾病、哮喘、花粉热、湿疹、癌症、结肠癌、胸腺瘤等，在哺乳动物体内，包括向哺乳动物体内施用上述式I化合物的治疗有效量，并制备包含式I化合物的药物的方法。
• FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS
  申请人：AMGEN INC.

  公开号：EP1791845A2

  公开（公告）日：2007-06-06
• US7674907B2
  申请人：——

  公开号：US7674907B2

  公开（公告）日：2010-03-09
• [EN] FURANOPYRIDINE DERIVATIVES AND METHODS OF USE<br/>[FR] DERIVES DE FURANOPYRIDINE ET LEURS PROCEDES D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2006130160A2

  公开（公告）日：2006-12-07

  [EN] The present invention relates to furanopyridine compounds having the general Formula I (I) and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of modulating Lck and ACK-1 enzymes and of treating various related diseases and conditions, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma, thymoma, just to name a few, in a mammal, comprising administering to the mammal a therapeutically effective amount a compound of Formula I, as described above, and methods of manufacturing medicaments comprising the compound of Formula I.
  [FR] La présente invention a trait à des composés de furanopyridine de formule générale (I) et leurs stéréoisomères, tautomères, solvates, sels et dérivés pharmaceutiquement acceptables, et prodrogues. L'invention a également trait à des compositions pharmaceutiques comportant un composé de formule I, à des procédés de modulation d'enzymes Lck et ACK-1 et de traitement de diverses maladies et conditions associées, comprenant l'inflammation, l'inhibition de l'activation des lymphocytes T, la prolifération, l'arthrite, la transplantation d'organes, la lésion ischémique ou de reperfusion répétée, l'infarctus du myocarde, l'accident vasculaire cérébrale, la sclérose en plaques, la maladie intestinale inflammatoire, la maladie de Crohn, le lupus, l'hypersensibilité, le diabète de type 1, le psoriasis, la dermatite, la thyroïdite d'Hashimoto, le syndrome de Sjögren, l'hyperthyroïdisme autoimmun, la maladie d'Addison, les maladies auto-immunes, la glomérulonéphrite, les maladies allergiques, l'asthme, le rhume de foins, l'eczéma, le cancer, le carcinome du côlon, le thymome, entre autres, chez un mammifère, comprenant l'administration au mammifère d'une quantité thérapeutiquement efficace d'un composé de formule I décrit plus haut, et à des procédés de fabrication de médicaments comportant le composé de formule I.
• Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: Synthesis, SAR, and pharmacokinetic properties
  作者：Matthew W. Martin、John Newcomb、Joseph J. Nunes、Jean E. Bemis、David C. McGowan、Ryan D. White、John L. Buchanan、Erin F. DiMauro、Christina Boucher、Theodore Faust、Faye Hsieh、Xin Huang、Josie H. Lee、Stephen Schneider、Susan M. Turci、Xiaotian Zhu

  DOI：10.1016/j.bmcl.2007.01.048

  日期：2007.4

  2,3-Diarylfuro[2,3-b]pyridine-4-amines are a novel class of potent and selective inhibitors of Lck. The discovery, synthesis, and structure activity relationships of this series of inhibitors are reported. The most promising compounds were also profiled to deduce their pharmacokinetic properties. (c) 2007 Elsevier Ltd. All rights reserved.